Interim analysis of the noninterventional study TILOT: Effectiveness and safety of tildrakizumab in long-term treatment of moderate to severe plaque psoriasis after 52 weeks in routine practice
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要